Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Behavior of Nasopharynx Malignancies: a Retrospective Study in a Ten-Year Sample

T. Kostlivy, P. Skopek, P. Klail, P. Hrabacka, M. Riant, A. Skalová, B. Gal, R. Kucera, V. Simanek, D. Slouka

. 2024 ; 45 (6) : 353-361. [pub] 20241210

Language English Country Sweden

Document type Journal Article

OBJECTIVES: Malignant tumors of the nasopharynx make up 3% of malignancies in the ENT area. The most common nasopharyngeal malignancy is nasopharyngeal carcinoma (NPC), followed by lymphomas. Other nasopharyngeal tumors are very rare. In this study, we aimed to assess the age distribution and behavior of the primary nasopharyngeal malignancies, NPC, and lymphoma over a ten-year period in a tertiary hospital patient group. DESIGN: Retrospective cohort study. MATERIAL AND METHODS: A total of 48 patients participated in this retrospective monocentric study. The group consisted of 13 females (27.1%) and 35 males (72.9%) diagnosed with nasopharyngeal malignancy and treated between 2012 and 2022. The patients' ages ranged from 14 to 83 years, with a mean age of 57.5 and a median of 55 years. The variables monitored in the study were histology, symptoms (such as nasal obstruction, Eustachian tube function, presence of glue ear, neck mass, weight loss), smoking status, TNM classification, and survival. RESULTS: In NPC grading and staging, two statistically significant variables were found to be associated with survival: distant metastases (p < 0.0001) and stage of the process (p = 0.0153). We did not find age and gender to be significant variables for lymphomas (p = 0.4066; p = 0.1797, respectively) or for NPC (p = 0.8630; p = 0.0573, respectively). Neither did we find any significant cut-off levels. In our analysis of therapy, we discovered that the use of chemoradiotherapy and palliative care in the NPC group is statistically significantly connected with disease-specific survival (p = 0.0094; p = 0.0004). This, however, was not the case in the lymphoma group. For the NPC group, we found statistically significant symptoms only in weight loss (p = 0.0081) and smoking (p = 0.0483). CONCLUSION: Our research confirmed that nasopharyngeal tumors are rare, with the most common type being nasopharyngeal carcinoma. In our patient group, 76.9% of cases involved nasopharyngeal cancer, which was five times more common in men than in women, and typically occurred in individuals over the age of 50. Lymphomas and other tumors accounted for less than a quarter of the cases. The overall five-year survival rate for nasopharyngeal malignancies in our group was 42.3%. We also observed an interesting gender perspective: 75% of women (6 women) survived for five years, whereas 72.2% of men died within five years of diagnosis.

000      
00000naa a2200000 a 4500
001      
bmc25010573
003      
CZ-PrNML
005      
20250429135148.0
007      
ta
008      
250415s2024 sw f 000 0|eng||
009      
AR
035    __
$a (PubMed)39732463
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Kostlivy, Tomas $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
245    14
$a The Behavior of Nasopharynx Malignancies: a Retrospective Study in a Ten-Year Sample / $c T. Kostlivy, P. Skopek, P. Klail, P. Hrabacka, M. Riant, A. Skalová, B. Gal, R. Kucera, V. Simanek, D. Slouka
520    9_
$a OBJECTIVES: Malignant tumors of the nasopharynx make up 3% of malignancies in the ENT area. The most common nasopharyngeal malignancy is nasopharyngeal carcinoma (NPC), followed by lymphomas. Other nasopharyngeal tumors are very rare. In this study, we aimed to assess the age distribution and behavior of the primary nasopharyngeal malignancies, NPC, and lymphoma over a ten-year period in a tertiary hospital patient group. DESIGN: Retrospective cohort study. MATERIAL AND METHODS: A total of 48 patients participated in this retrospective monocentric study. The group consisted of 13 females (27.1%) and 35 males (72.9%) diagnosed with nasopharyngeal malignancy and treated between 2012 and 2022. The patients' ages ranged from 14 to 83 years, with a mean age of 57.5 and a median of 55 years. The variables monitored in the study were histology, symptoms (such as nasal obstruction, Eustachian tube function, presence of glue ear, neck mass, weight loss), smoking status, TNM classification, and survival. RESULTS: In NPC grading and staging, two statistically significant variables were found to be associated with survival: distant metastases (p < 0.0001) and stage of the process (p = 0.0153). We did not find age and gender to be significant variables for lymphomas (p = 0.4066; p = 0.1797, respectively) or for NPC (p = 0.8630; p = 0.0573, respectively). Neither did we find any significant cut-off levels. In our analysis of therapy, we discovered that the use of chemoradiotherapy and palliative care in the NPC group is statistically significantly connected with disease-specific survival (p = 0.0094; p = 0.0004). This, however, was not the case in the lymphoma group. For the NPC group, we found statistically significant symptoms only in weight loss (p = 0.0081) and smoking (p = 0.0483). CONCLUSION: Our research confirmed that nasopharyngeal tumors are rare, with the most common type being nasopharyngeal carcinoma. In our patient group, 76.9% of cases involved nasopharyngeal cancer, which was five times more common in men than in women, and typically occurred in individuals over the age of 50. Lymphomas and other tumors accounted for less than a quarter of the cases. The overall five-year survival rate for nasopharyngeal malignancies in our group was 42.3%. We also observed an interesting gender perspective: 75% of women (6 women) survived for five years, whereas 72.2% of men died within five years of diagnosis.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory nosohltanu $x terapie $x mortalita $x patologie $x epidemiologie $7 D009303
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a lymfom $x epidemiologie $x terapie $x mortalita $7 D008223
650    _2
$a nasofaryngeální karcinom $x terapie $x mortalita $x patologie $7 D000077274
650    _2
$a staging nádorů $7 D009367
650    _2
$a karcinom $x patologie $x terapie $x epidemiologie $x mortalita $7 D002277
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skopek, Petr $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Klail, Pavel $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Hrabacka, Petr $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Riant, Michal $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Skalová, Alena $u Department of Pathology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Gal, Bretislav $u Department of of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kucera, Radek $u Institute of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Simanek, Vaclav $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
700    1_
$a Slouka, David $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic
773    0_
$w MED00168352 $t Neuro-endocrinology letters $x 2354-4716 $g Roč. 45, č. 6 (2024), s. 353-361
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39732463 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135143 $b ABA008
999    __
$a ok $b bmc $g 2311754 $s 1247654
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 45 $c 6 $d 353-361 $e 20241210 $i 2354-4716 $m Neuro-endocrinology letters $n Neuro Endocrinol Lett $x MED00168352
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...